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Simple Summary: The formation of normal blood cells in the bone marrow is supported by a network
of non-hematopoietic cells including connective tissue cells, blood vessel cells and bone-forming
cells. These cell types support and regulate the growth of acute myeloid leukemia (AML) cells
and communicate with leukemic cells through the release of proteins to their common extracellular
microenvironment. One of the AML-supporting normal cell types is a subset of connective tissue
cells called mesenchymal stem cells. In the present study, we observed that AML cells release a wide
range of diverse proteins into their microenvironment, but patients differ both with regard to the
number and amount of released proteins. Inhibition of this bidirectional communication through
protein release between AML cells and leukemia-supporting normal cells may become a new strategy
for cancer treatment.
Abstract: Extracellular protein release is important both for the formation of extracellular matrix
and for communication between cells. We investigated the extracellular protein release by in vitro
cultured normal mesenchymal stem cells (MSCs) and by primary human acute myeloid leukemia
(AML) cells derived from 40 consecutive patients. We observed quantifiable levels of 3082 proteins
in our study; for the MSCs, we detected 1446 proteins, whereas the number of released proteins
for the AML cells showed wide variation between patients (average number 1699, range 557–2380).
The proteins were derived from various cellular compartments (e.g., cell membrane, nucleus, and
cytoplasms), several organelles (e.g., cytoskeleton, endoplasmatic reticulum, Golgi apparatus, and
mitochondria) and had various functions (e.g., extracellular matrix and exosomal proteins, cytokines,
soluble adhesion molecules, protein synthesis, post-transcriptional modulation, RNA binding, and
ribonuclear proteins). Thus, AML patients were very heterogeneous both regarding the number of
proteins and the nature of their extracellularly released proteins. The protein release profiles of MSCs
and primary AML cells show a considerable overlap, but a minority of the proteins are released
only or mainly by the MSC, including several extracellular matrix molecules. Taken together, our
observations suggest that the protein profile of the extracellular bone marrow microenvironment
differs between AML patients, these differences are mainly caused by the protein release by the
leukemic cells but this leukemia-associated heterogeneity of the overall extracellular protein profile
is modulated by the constitutive protein release by normal MSCs.
Keywords: acute myeloid leukemia; mesenchymal stem cells; protein; proteomics; extracellular
protein release; conditioned medium; patient heterogeneity
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1. Introduction
Acute myeloid leukemia (AML) is an aggressive malignancy arising from hematopoi-
etic stem cells, and the median age at the time of first diagnosis is 65–70 years [1]. Acute
promyelocytic leukemia (APL) is an AML subtype characterized by specific genetic abnor-
malities, different treatment and better prognosis than non-APL AML [2]. In our present
study, we investigated patients with non-APL variants of the disease, and the term AML in
this article therefore refers to the non-APL variants of AML [3].
AML is an aggressive malignancy; the only possibility for cure is intensive chemother-
apy, possibly including allogeneic stem cell transplantation. However, patients with
poor-risk genetic features have a very high risk of chemoresistant disease or relapse [1].
Many elderly and unfit patients can only receive supportive care and have a median
survival of 1–3 months after diagnosis [1]. Furthermore, most elderly patients cannot
receive the intensive treatment due to an unacceptable risk of severe complications and
treatment-related mortality [1]. Thus, there is a need for more effective and less toxic
treatment in AML that can be used in combination with the conventional intensive therapy
for younger patients and/or as a less toxic treatment in elderly/unfit patients.
The proliferation and survival of primary human AML cells is supported by neigh-
boring non-leukemic stromal cells in the bone marrow microenvironment, including the
mesenchymal stem/stromal cells (MSCs) that are a part of the normal bone marrow stem
cell niches [4–11]. Even though the AML cell population has a hierarchical organization and
the minority of AML stem cells are regarded as essential for development of chemoresistant
leukemia relapse [6], the AML-supporting extracellular bone marrow microenvironment
is influenced by the total AML cell population and not only the very small minority of
leukemic stem cells [7]. This is further supported by the observations from a previous study
describing an association between the constitutive cytokine release profile and AML-free
survival (i.e., reflecting a decreased risk of chemoresistant relapse) [8]. The constitutive
extracellular protein release is probably important for the bidirectional crosstalk that can
influence the functional characteristics of both the leukemic and stromal cells [9–11]. Our
hypothesis was that AML patients are heterogeneous also with regard to the constitutive
protein release by their leukemic cells, but the effect of this heterogeneity on the common
extracellular microenvironment of AML and stromal cells is modulated by the constitutive
release by stromal cells. In this context, we have characterized the overall extracellular
protein release profiles for AML cells derived from 40 consecutive patients. We describe
the variation of the in vitro constitutive extracellular protein release between patients and
how the extracellular MSC protein release is modulated by primary human AML cells.
2. Materials and Methods
2.1. AML Patients and Preparation of Enriched AML Cells
Primary human AML cells were derived from the peripheral blood of 40 patients
after written informed consent and in accordance with the Declaration of Helsinki (see
Table 1 and Table S1). The Regional Ethics Committee approved both the collection of
biological material in the biobank (REK Vest 2015/1759) and the use of the cells in the
present study (REK Vest 2017/305). All AML patients had a relatively high peripheral
blood level and percentage among circulating leukocytes of AML cells (AML cell concen-
tration >15 × 109/L, >80% of circulating leukocytes being AML cells), and highly enriched
AML cell population (>95%) could therefore be prepared by density gradient separation
alone (Lymphoprep, Axis-Shield, Norway). The cells were stored cryopreserved in liquid
nitrogen until used. Only 19 patients received intensive antileukemic treatment; 4 patients
died from treatment-related toxicity and 11 of the 15 patients who completed the planned
intensive antileukemic treatment later died from chemoresistant relapse.
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Table 1. Clinical and biological characteristics of the 40 AML patients included in this study. Unless otherwise stated, the
results are presented as the number of patients.
Characteristics (n = 40)
Sex and age Karyotype/Karyotype Abnormalities
Males/females 21/19 Normal 20
Age median (range) in years 71 (18–87) Favorable 4
Intermediate 9
Predisposition/previous disease Adverse 4
Previous chronic myeloid neoplasia 1 Not tested 3
Myelodysplastic syndrome 8
Relapsed AML 3 Flt3 abnormalities
Chemotherapy related 0 ITD 13
Wild type 19
Morphology/FAB classification Not tested 8
M0/M1 17
M2 8 NPM1 abnormalities
M4/M5 15 Insertion 13
M6/M7 0 Insertion + Flt3-ITD 8
Wild type 20
CD34 positive 21 Not tested 7
Abbreviations: FAB, French-American-British; ITD, internal tandem duplication.
Cryopreserved human MSCs from bone marrow (> 500,000 cells) of a healthy 73-
year-old female donor (C-12974; lot number 427Z010.1) were purchased from PromoCell
Gmbh (Heidelberg, Germany). These cells had been cryopreserved in passage two and
the MSC phenotype was verified by flow cytometric analysis and cell morphology; the
proliferation potential, adherence rate and viability were also documented and the cells
had the capacity to differentiate into the various mesenchymal lineages. The cells were
shipped and stored in liquid nitrogen until use. The MSCs were adherent, showed a normal
morphology judged by light microscopy and a typical protein release profile when cultured
in serum-free medium (see Section 2.2) [12].
2.2. Cell Culture
Primary AML cells were cultured at a concentration of 10 × 106 cells/mL (10 mL
medium per flask) in T25 flasks (Falcon; Glendale, AZ); the culture medium was serum-free
IMDM without phenol red (Ref. 21056023, ThermoFisher Scientific; Waltham, MA, USA).
The supernatants (referred to as AML-conditioned media; AML-CM) were collected after
48 h and stored in aliquots at −80 ◦C, as described previously [12].
MSCs were thawed according to the manufacturer’s instructions and 5 × 105 cells were
expanded to 4 × 106 cells in Mesenchymal Stem Cell Growth Medium (Promocell Gmbh)
before the cells were distributed into four T75 flasks (Falcon) after eight days of culture.
The cells were cultured for three additional days before the medium was changed to IMDM,
thereafter transferred to 24-well culture plates (Falcon) (3 × 104 cells/well) and cultured
in Mesenchymal Stem Cell Growth Medium for one day before the medium was again
changed to serum-free IMDM. AML-CM (also prepared in serum-free IMDM) were added
at a ratio of 1:1 (supernatant:IMDM). MSCs were cultured in the presence of AML-CM
for 48 h before supernatants were collected (referred to as MSC/AML-CM). Six replicates
of MSCs were also cultured without AML-CM, and one aliquot of the MSC donor was
cultured in a T25 flask under the same conditions as the AML cells. The supernatants were
stored in aliquots at −80 ◦C until analyzed. An overview of the experimental workflow is
summarized in Figure 1.
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Figure 1. Experimental workflow. Conditioned media (CM) samples from 40 AML patient cell cultures were collected in 
two aliquots, of which one was analyzed alone (i.e., AML-CM) and one was added to MSC cultures derived from one 
donor in ratio 1:1 (i.e., MSC/AML-CM). Medium without AML-CM was added to six MSC cultures (i.e., MSCs alone). One 
aliquot of the MSC donor cells was also cultured under the same conditions as the AML cell cultures (not included in the 
figure). See Section 2.2 for details. 
Figure 1. Experimental workflow. Conditioned media (CM) samples from 40 AML patient cell cultures w re collected in
two aliquots, of which one as analyzed alone (i.e., AML-CM) and one was added to MSC cultures derived from one donor
in ratio 1:1 (i.e., MSC/AML-CM). Medium without AML-CM was added to six MSC cultures (i.e., MSCs alone). One aliquot
of the MSC donor cells was also cultured under the same conditions as the AML cell cultures (not included in the figure).
See Section 2.2 for details.
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2.3. Proteomics Sample Preparation and Liquid Chromatography (LC)–Tandem Mass Spectrometry
(MS/MS) Analysis
Proteomic sample preparation and liquid chromatography (LC)–tandem mass spec-
trometry (MS/MS) analysis has been described previously [12].
2.4. Statistical and Bioinformatical Analyses
Analysis of the LC–MS/MS raw files in MaxQuant (version 1.6.1.0; Max Planc In-
stitute for Biochemistry, Martinsread, Germany) [13,14] and further data processing in
Perseus (version 1.6.1.1; Max Planck Institute for Biochemistry) [15] has been described
previously [12]. Funrich version 3.1.3 [16] and a GO tool [17] (selecting the filter hierarchy
option for the results) was used for GO analyses, and GO terms with FDR < 0.05 were
considered as significantly enriched. Graphpad Prism (version 8, San Diego, CA, USA)
was used to generate correlation and bar plots. Welch’s t-test was used to find proteins with
significantly different abundance of proteins in the groups, except for the corresponding
AML-CM and MSC/AML-CM pairs where a paired t-test was used. Z-statistics [18] was
used in addition to Welch’s t-test to find significantly different fold changes between the
main patient clusters constructed by hierarchical clustering analysis of the AML-CM dataset
(Section 3.3). Furthermore, we required a four-fold reduction or two-fold increase in protein
abundance when comparing MSC/AML-CM to AML-CM because the MSC/AML-CM
samples were cultured in 50% AML-CM. Protein interaction network analysis was per-
formed with the String database (version 11.0) [19] and Cytoscape (version 3.3.0; National
Institute of General Medical Sciences, Bethesda, MD, USA) [20] as previously described [12],
except that MCODE (version 2.0) was used to classify densely connected protein networks
of high cohesiveness [21].
3. Results
3.1. Constitutive Extracellular Protein Release by AML; Characterization of Patient Heterogeneity
and the Overlap with MSC Release
Primary AML cells from 40 patients (Table S1, Figure 1) were cultured in serum-free
medium for 48 h before the supernatants were collected; these supernatants will also be
referred to as conditioned medium (AML-CM). A total of 3026 proteins were quantified for
the 40 patients (Supplementary File 2), but the number of quantified proteins per patient
varied from 557 to 2380 proteins (Figure 2, left). The abundance of released proteins was
significantly correlated between patients except for the two outlier patients P114 and P127
(Figure 2, right).
Among the 3026 different proteins released by primary human AML cells, 435 proteins
were quantified in AML-CM for at least 38 patients (161 expressed in all 40 patients),
whereas 415 proteins were quantified in AML-CM for five or fewer patients (98 proteins
only in one patient each). Only 1770 proteins were quantified for at least 50% of the AML
patients. These observations clearly illustrate that there is a considerable variation between
patients regarding the number and identity of proteins released during in vitro culture.
We also compared proteins released by the 40 AML cell populations with the pro-
teins released by the 7 MSC replicates derived from our healthy donor. We quantified
1446 proteins released by the MSCs, of which 800 proteins were observed for at least four
of the replicate samples; these proteins are thus released at relatively high concentrations
so that they reach detectable levels in most replicates despite the minor variations between
these seven independent experiments/replicates. The MSCs cultured alone showed a large
overlap with the AML-CM as only 32 of the 1446 proteins were not quantified for any AML
patient (Figure 3A). A total of 61 MSC proteins were quantified for two or fewer of the
AML patients but at least four MSC cultures (Figure 3B, Table S2), and 16 of these were not
released by any AML cell population in our study. Thus, the MSCs released relatively few
unique proteins compared with many primary AML cell populations, and there was in
addition a large overlap between leukemic cells and MSCs in their extracellular protein
release with only a minority of the MSC-released proteins showing undetectable levels for
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all or most AML patients. Furthermore, we found several interacting proteins in an interac-
tion network analysis based on the 61 proteins predominantly released by MSCs, and the
proteins were annotated to GO terms as secreted, signal and extracellular matrix (Figure S1).
The 16 MSC-specific proteins as well as the proteins detected only for two or fewer AML
patients were very heterogeneous and included extracellular matrix proteins, cytokines
and cytokine receptors, soluble adhesion molecules and proteases (Table S2 and Figure S1).




Figure 2. The heterogeneity in constitutive protein release by primary human AML cells; a comparison of leukemic cells 
derived from 40 patients. The cells were cultured for 48 h in serum-free medium before supernatants were harvested and 
the proteomic analyses performed. (Left figure) The figure presents the number of detectable proteins for each of the 40 
patients. The number of quantified proteins varied from 557 to 2380 proteins (1699 proteins in average, vertical dotted 
line) between individual patients. (Right figure) The heatmap of the Pearson Correlation R values illustrates how well the 
protein expression correlates between the 40 AML patients, i.e., the patients showed a large degree of overlap with regard 
to the abundance of proteins released. This analysis is based on the 1770 proteins detected for at least 20 of the 40 AML-
CM samples. 
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and the proteomic analyses performed. (Left figure) The figure presents the number of detectable proteins for each of the
40 patients. The number of quantified proteins varied from 557 to 2380 proteins (1699 proteins in average, vertical dotted
line) between individual patients. (Right figure) The heatmap of the Pearson Correlation R values illustrates how well
the protein expression correlates between the 40 AML patients, i.e., the patients showed a large degree of overlap with
regard to the abundance of proteins released. This analysis is based on the 1770 proteins detected for at least 20 of the
40 AML-CM samples.
3.2. Primary Human AML Cells Release of Proteins Derived from Different
Cellular Compartments
GO analysis (using FunRich) of cellular compartment based on all identified proteins
showed that 68% were annotated to the cytoplasm, 55% to the nucleus and 44% to exosomes
(Table 2). More than 300 proteins were also annotated to the plasma membrane. Thus,
the released proteins are derived from various cellular compartments or intracellular
organelles. Analysis of the GO terms with regard to molecular functions also demonstrated
that the released proteins are very heterogeneous (Table S3). Large subsets of proteins
were classified as ribosomal/RNA binding proteins, DNA binding proteins, transcriptional
regulators, cytoskeleton binding protein or having catalytic, chaperone or transporter
activity. Finally, the most significant biological processes identified through GO term
an lyses w re prot in metabolism (322 proteins, corr cted p-value 5.87 × 10−57), nergy
pathways (p-valu 3 × 10−18) and cell growth and/or maintenance (p-value 0.00049).
Taken toge er, these last analyses indicate that the AML cells release a wid range of
non-extracellular matrix pro eins derived from various intracellular compartments and
reflecting diff rent intrac llular processes.
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total, 61 proteins (45 + 16) were more often released by the MSCs as they were found in only two or fewer AML-CM samples.
Table 2. GO analysis of all gene/protein names identified in this study, i.e., all proteins identified for the MSCs cultured
alone, 40 primary AML cells cultured alone (AML-CM) and/or MSCs cultured in the presence of AML-conditioned medium
(MSC/AML-CM). The presentation is based on a bioinformatical analysis of GO terms/cellular compartment, and the list
presents all terms that included at least 100 of the identified proteins (hypergeo etric test, Bonferroni correction). The data
are presented as the number of proteins associated to a given term, number of proteins in the background dataset, percent
of proteins in the dataset annotated to a given GO term, the fold enrichment and the p-values.













Cytoplasm 1171 5684 68.4 1.8 2.2 × 10−151 1.7 × 10−148
Nucleus 946 5847 55.3 1.4 2.83 × 10−41 2.22 × 10−38
Exosomes 746 2043 43.6 3.1 5.8 × 10−232 4.5 × 10−229
Lysosome 561 1620 32.8 2.9 1.8 × 10−151 1.4 × 10−148
Nucleolus 443 1257 25.9 3.0 1.4 × 10−118 1.1 × 10−115
Cyt sol 407 1178 23.8 2.9 1.5 × 10−104 1.1 × 10−101
Mitochondrion 348 1259 20.3 2.4 2.36 × 10−59 1.85 × 10−56
Centrosome 343 656 20.0 4.4 4.8 × 10−152 3.7 × 10−149
Plasma membrane 316 3479 18.5 0.8 1 1
Extracellular 262 1825 15.3 1.2 0.000182 0.14294
Endoplasmic reticulum 148 1104 8.6 1.1 0.044427 1
Cytoskeleton 137 427 8.0 2.7 7.52 × 10−30 5.89 × 10−27
Golgi apparatus 127 897 7.4 1.2 0.013653 1
Nucleoplasm 106 449 6.2 2.0 7.13 × 10−13 5.59 × 10−10
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3.3. Subclassification of AML Patients Based on the Constitutive Protein Release Profile of Their In
Vitro Cultured Leukemic Cells
In the present study, we included consecutive AML patients which were hetero-
geneous in terms of clinical and biological characteristics (Table S1). We performed a
hierarchical clustering analysis based on the 1770 of the 3026 AML-released proteins
that could be quantified for at least 50% of the patients; the influence of exceptional
proteins/patients on this analysis of protein/patient subclassification was thereby re-
duced (Figure 4, Supplementary File 2). These released proteins formed five different
clusters as indicated by the colors at the top of Figure 4 (purple, green, yellow, orange
and blue clusters), and the enriched GO terms differed between each of these five protein
clusters (Table 3).




Figure 4. Identification of AML patient subsets based on their constitutive protein release during in vitro culture; an un-
supervised hierarchical cluster analysis including 40 patients and based on 1770 proteins detected for at least 50% of the 
patients. The cells were cultured for 48 h in serum-free medium before supernatants were harvested and the proteomic 
analyses performed. The patients clustered into two main clusters (yellow/upper and brown/lower; see the column on the 
right side of the clustering); each of these two main clusters had two subclusters (upper yellow/dark yellow and lower 
brown/dark brown, respectively). As can be seen from the upper part of the figure, the proteins clustered into five main 
clusters each including 392 proteins (Cluster 1, purple), 460 proteins (Cluster 2, green), 337 proteins (Cluster 3, yellow), 
417 proteins (Cluster 4, orange) and 164 proteins (Cluster 5, blue), respectively. Patient characteristics are indicated to the 
right in the figure, and blank fields indicate information not determined. Black color in the cluster analysis indicates that 
the protein was not detected. 
Table 3. Hierarchical clustering of AML patients based on the constitutive protein release profiles 
of their leukemic cells during in vitro culture. The table gives an overview of the most significant 
GO terms for each of the five identified protein clusters (see Figure 4, upper part indicating the 
protein clustering). For each of the five protein clusters, we present the five most significant GO 
terms (Cellular compartment). 
Cluster and Corresponding Go Terms p-Value (Uncorrected) FDR 
Left purple protein cluster   
Mitochondrial part 7.77 × 10−8 4.68 × 10−5 
Ribosomal subunit 1.72 × 10−6 0.000345 
Organelle inner membrane 1.41 × 10−5 0.00212 
Cytosolic part 1.48 × 10−5 0.00212 
Mitochondrion 1.86 × 10−5 0.00212 
Middle left green protein cluster   
Nucleoplasm part 7.69 × 10−7 0.000557 
Nucleoplasm 0.000116 0.0168 
Spliceosomal complex 0.000621 0.0749 
Nuclear chromosome part 0.00125 0.113 
Nucleoplasm part 7.69 × 10−7 0.000557 
Figure 4. Identification of AML patient subsets based on their constitutive protein release during in vitro culture; an
unsupervised hierarchical cluster analysis including 40 patients and based on 1770 proteins detected for at least 50% of the
patients. The cells ere cultured for 48 h in seru -free edium before supernatants were harvested and the proteomic
a al ses rf r . l t ( ll u per and brown/lower; see the column on the
ri t si f t cl s t clusters (upper ye low/dark yellow and lower
bro n/dark bro n, respectively). As can be seen from the upper part of the figure, the proteins clustered into five main
clusters each including 392 proteins (Cluster 1, purple), 460 proteins (Cluster 2, green), 337 proteins (Cluster 3, yellow), 417
proteins (Cluster 4, orange) and 164 proteins (Cluster 5, blue), respectively. Patient characteristics are indicated to the right
in the figure, and blank fields indicate information not determined. Black color in the cluster analysis indicates that the
protein was not detected.
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Table 3. Hierarchical clustering of AML patients based on the constitutive protein release profiles of their leukemic cells
during in vitro culture. The table gives an overview of the most significant GO terms for each of the five identified protein
clusters (see Figure 4, upper part indicating the protein clustering). For each of the five protein clusters, we present the five
most significant GO terms (Cellular compartment).
Cluster and Corresponding Go Terms p-Value (Uncorrected) FDR
Left purple protein cluster
Mitochondrial part 7.77 × 10−8 4.68 × 10−5
Ribosomal subunit 1.72 × 10−6 0.000345
Organelle inner membrane 1.41 × 10−5 0.00212
Cytosolic part 1.48 × 10−5 0.00212
Mitochondrion 1.86 × 10−5 0.00212
Middle left green protein cluster
Nucleoplasm part 7.69 × 10−7 0.000557
Nucleoplasm 0.000116 0.0168
Spliceosomal complex 0.000621 0.0749
Nuclear chromosome part 0.00125 0.113
Nucleoplasm part 7.69 × 10−7 0.000557
Middle yellow protein cluster
Extracellular exosome 4.72 × 10−17 2.97 × 10−14
Cytoplasmic vesicle part 1.68 × 10−9 1.76 × 10−7
Cytosol 1.80 × 10−9 1.76 × 10−7
Extracellular region 1.42 × 10−8 1.11 × 10−6
Vesicle lumen 1.42 × 10−7 7.43 × 10−6
Middle right orange protein cluster
Extracellular matrix organization 2.67 × 10−10 1.33 × 10−6
Anatomical structure morphogenesis 1.96 × 10−5 0.0325
Positive regulation of developmental process 0.000231 0.231
Vesicle-mediated transport 0.000237 0.231
Multicellular organismal process 0.000243 0.231
Right blue protein cluster
No significant GO terms
The left purple cluster especially included proteins from the cytoplasm or various
cytoplasmic organelles, the middle left green cluster especially nuclear proteins, the middle
yellow cluster especially exosomal/vesicular/extracellular proteins, the orange middle
right cluster especially extracellular matrix proteins as well as proteins involved in in-
tracellular vesicle-mediated transport, while no GO terms were significantly enriched in
right blue cluster. The clustering analysis (Figure 4) identified two main patient clusters
indicated by yellow (cluster 1; upper) and brown color (cluster 2; lower) to the right in
the figure. Each of the two main patient clusters included two subclusters indicated by
bright yellow/yellow and brown/dark brown, respectively. The four subclusters differed
significantly when analyzing the number of quantified proteins in each cluster (Kruskal–
Wallis test, p = 0.0001); patients in the lower brown main cluster generally released higher
numbers of proteins (cluster 2; 23 patients, median number 2030 proteins, range 1686–2380)
compared with the patients in the upper yellow main cluster (cluster 1; 17 patients, median
number 1282, range 557–1864, Wilcoxon’s test, p = 0.0034).
A statistical analysis based on the proteins in the two main clusters (Figure 4; main
yellow/cluster 1 and brown/cluster 2) resulted in 144 proteins with significantly different
protein abundance, using Welch’s t-test and Z-statistics. Several interacting proteins were
identified in interaction network analyses (Figure S2), and three networks showed densely
connected proteins (Figure 5). Network 1 was dominated by ribosomal proteins and
included 12 proteins mainly belonging to the purple protein cluster (see Figure 4, upper
part). Network 2 was enriched with proteins annotated to secretory granules and with
all ten proteins belonging to the middle yellow or orange protein clusters (Figure 4). The
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mRNA processing proteins in network 3 did not belong to any specific protein cluster. The
patients in cluster 2 (lower brown cluster in Figure 4) thus seem to have higher abundance
of several ribosomal and secretory granule proteins compared to the patients in cluster 1
(upper yellow cluster).
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cation (see Figure S2 for the complete network). The color coding indicates the protein fold change 
(log2 transformed) between cluster 2 and 1, where turquoise illustrates increased abundance and 
orange illustrates decreased abundance in the lower main cluster 2. 
The difference in the number of released proteins between the two yellow/upper sub-
clusters reached only borderline significance (p = 0.0455), the patients in the bright yellow 
upper subcluster showing reduced release especially of proteins in the middle right 
brown protein clusters (exosomal/extracellular and nuclear proteins). In contrast, the pa-
tients in the lower yellow subcluster showed a generally reduced number of released ex-
tracellular proteins, and this patient subcluster also included a significantly increased 
number of patients with secondary AML (CMML or MDS; Fisher’s exact test, p = 0.0197). 
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Previous studies have shown that AML patients differ with regard to the prolifera-
tive capacity and the degree of spontaneous apoptosis during in vitro culture of their leu-
kemic cells [22,23]. However, the proliferative capacity after seven days of in vitro culture 
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in Figure 4. A large protein interaction network was generated in String and imported into Cytoscape to find densely
connected proteins using the MCODE application (see Figure S2 for the complete network). The color coding indicates
the protein fold change (log2 transformed) between cluster 2 and 1, where turquoise illustrates increased abundance and
orange illustrates decreased abundance in the lower main cluster 2.
The difference in the number of released proteins between the two yellow/upper
subclusters reached only borderline significance (p = 0.0455), the patients in the bright
yellow upper subcluster showing reduced release especially of proteins in the middle right
brown protein clusters (exosomal/extracellular and nuclear proteins). In contrast, the
patients in the lower yellow subcluster showed a generally reduced number of released
extracellular proteins, and this patient subcluster also included a significantly increased
number of patients with secondary AML (CMML or MDS; Fisher’s exact test, p = 0.0197).
As would then be expected this cluster also included a larger fraction of patients above
70 years of age (7/8 versus 14/18; Fisher’s exact test, p = 0.0461); younger patients were
especially seen in the lower dark brown cluster. Furthermore, the patient clusters did
not differ significantly with regard to gender, differentiation (FAB classification/CD34
expression) karyotype or Flt3/NPM1 abnormalities. Finally, the patients in the lowest dark
brown subcluster showed high levels of proteins in the middle yellow protein cluster that
especially included exosomal/vesicular/extracellular proteins (e.g., collagen trimer and
endoplasmic reticulum proteins). Thus, AML patients can be further subclassified into
distinct subsets based on the number and nature of constitutively released proteins by
their AML cells, and these differences correspond to differences in important functional
cell characteristics.
Previous studies have shown that AML patients differ with regard to the proliferative
capacity and the degree of spontaneous apoptosis durin in vitro culture of their leukemic
cells [22,23]. However, he proliferative capacity after seven days of in vitro culture and
the percentage of viable cells after two da s of culture id n t differ significantly between
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the two main patient clusters or between the subclusters (see Figures 4 and 6) identi-
fied by the cluster analysis presented in Figure 4. Thus, even though protein release by
necrotic/apoptotic cells during in vitro culture may contribute to the extracellular protein
release of our cultured AML cells, such differences seem to be relatively small and cannot
explain the patient subset classification identified in Figure 4.
AML patients differ in the capacity of their leukemic cells to constitutively release
cytokines/chemokines and proteases/protease inhibitors during in vitro culture and based
on these differences patients can be classified as showing generally high, intermedi-
ate/variable and low constitutive release of these mediators [8,24–27]. Soluble mediator
release data were available for 33 (unselective/consecutive) of our 40 AML patients (i.e.,
antibody-mediated estimation of soluble mediator levels in supernatants), and these re-
sults confirmed that patients could be classified into three main subsets based on their
capacity of constitutive cytokine release (Figure S3). High constitutive cytokine release was
observed especially for patients in the lowest dark brown patient subcluster characterized
by generally high constitutive protein release (8 out of 10 patients); this is significantly
different from the other patients (5 out of 17, Fisher’s exact test, p = 0.0183). Thus, the
release of a high number of extracellular proteins (i.e., a characteristic of the lower brown
main cluster, see above) is associated with a high capacity of cytokine/chemokines and
proteases/protease inhibitor release.
3.4. The AML-Associated Heterogeneity of the Extracellular Protein Profile Is Largely Maintained
also in the Presence of MSCs
Most of the quantified proteins released by MSCs were also released by primary AML
cells, but as described above, the number of AML cell populations with detectable levels of
each individual protein showed wide variation. MSC cultures were therefore prepared in
medium alone and in medium supplemented with AML-CM (referred to as MSC/AML-
CM) (Figure 1). All 40 leukemia patients were included in these experiments, and we first
did a correlation analysis including all detectable proteins and all 40 patients to investigate
whether the presence of protein-releasing MSCs reduced the patient heterogeneity. We
observed a strong correlation between the number of patients with detectable levels of indi-
vidual proteins in the AML-CM and in the supernatants from MSC cultures supplemented
with the corresponding AML-CM (Spearman Rank Correlation test, r = 0.8019, p < 0.00005).
Thus, for the large majority of released proteins the fraction of patients with detectable
levels is comparable when AML cells are cultured alone (i.e., AML-CM) and when MSCs
are cultured with the same AML-conditioned medium. Finally, we also performed similar
correlation analyses based on protein subsets that are important for cellular communica-
tion or adhesion, and similar strong associations were also observed when only including
defined protein subsets, i.e., 80 extracellular matrix molecules (Spearman’s rho, 0.667), 67
soluble extracellular mediators (cytokines/chemokines/growth factors (Spearman’s rho,
0.803) and 300 proteins included in the GO term Protease (Spearman’s rho, 0.785).
3.5. Reduction in Patient Heterogeneity by MSCs; a Small Subset of Proteins Show Heterogeneous
AML Cell Release but Are Released at High Levels by MSCs
Even though patient heterogeneity seems to be largely maintained even in the presence
of MSCs (see Section 3.4), we identified a minority of 60 deviating proteins (Table 4); these
proteins were released at quantifiable levels only for 10 or fewer of the 40 patients when
AML cells were cultured alone (i.e., in AML-CM) but showed quantifiable levels for at least
30 patients when MSCs were cultured with AML-CM. All these 60 proteins were released
at high levels when MSCs were cultured alone, and they included 24 extracellular matrix
proteins (5 collagens), 10 cell surface/adhesion molecules and 8 enzymes (see detailed
description in Table S4).
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Figure 6. Identification of AML patient subsets by hierarchical clustering analysis of constitutive leukemic cell protein 
release. The AML cells were derived from 40 patients, and the cells were cultured alone for 48 h in serum-free medium 
before supernatants were analyzed. The number of quantified proteins varied from 557 to 2380 proteins (average 1699 
proteins), and the proteomic analysis was based on the 1770 proteins detected in 50% or more of the AML-CM samples. 
Figure 6. Identification of AML patient subsets by hierarc ical clustering analysis of constitutive leukemic cell protein
release. The AML cells were derived from 40 patients, and the cells were cultured alone for 48 h in serum-free medium before
supernatants were analyzed. The number of quantified proteins varied from 557 to 2380 proteins (average 1699 proteins),
and the proteomic analysis was based on the 1770 proteins detected in 50% or more of the AML-CM samples. This
clustering analysis is presented in Figure 4; two main clusters each with two subclusters were identified (left and right part,
respectively, of the present Figure 6), and the patients are listed from the upper part to the bottom of the present figure
according to the results from this clustering analysis (patient identity columns). For 33 patients we also analyzed their
release of 19 selected soluble mediators for AML cells cultured alone using antibody-based methodology (Figure S3); a
hierarchical clustering analysis based on these mediator levels classified the patients into three main subsets with generally
low, intermediate and high constitutive mediator release (see upper right). The column Cytokine release cluster refers to
this classification, and the color codes are explained in the lower left part of the figure. Finally, we also did a hierarchical
clustering analysis based on the protein release profile of all 40 patients when MSCs were cultured with AML-CM for
all 40 patients (Figure S4). The subclusters/subclassification of patients based on this last analysis is summarized in the
column referred to as MSC/AML-CM cluster (color code explanation, see lower left). The right part of the figure presents
the number of quantified proteins and the number of viable AML cells after 48 h of in vitro culture for each patient sample.
The median and range of quantified proteins/viability for each of the four patient subsets are presented to the right in each
part of the figure.
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Table 4. An overview of 60 individual proteins that showed detectable constitutive release by the AML cells for 10 or
fewer of the 40 patients (i.e., detected in AML-CM), but showed detectable supernatant levels for at least 30 patients when
MSCs were cultured with AML-CM (i.e., MSC/AML-CM). All proteins were quantified in at least five of the seven culture
replicates of MSCs alone. The classification is based on information in the Gene database. Proteins that are important for the
support of normal hematopoietic stem cells are marked in the table [28–32].
All identified proteins
(alphabetic order)
ABI3BP, B4GALT1, BGN, C1R, CD248, CDH2, CDH11, CDH13,
CFH, COL10A1, COL16A1, COL18A1, COL4A1, COL8A1,
CRIM1, CTGF, CTHRC1, CTSK, CYR61, DAG1, DKK3, ECM1,
ENPP1, ENPP2, FBLN1, FBLN5, FKBP10, GAS6, GOLM1,
GREM1, IGFBP4, ISLR, ITGBL1, LAMA4, LOX, LOXL1,
LOXL2, MFAP2, MMP13, MMP14, MXRA8, NBL1, NRP2,
OLFML2B, PAPPA, PLOD2, PLTP, PROCR, PRSS23, PTPRK,
SDC1, SMOC1, SPON2, SRPX2, SSC5D, STC2, TAGLN, THY1,
TNC, VASN
Extracellular matrix (ECM) molecules
ABI3BP, BGN, COL10A1, COL16A1, COL18A1, COL4A1,
COL8A1, ECM1, FBLN1, FBLN5, ISLR, LAMA4, MFAP2,
MXRA8, SMOC1, SPON2, SRPX2, STC2, TNC
ECM modulators: LOX, LOXL1, LOXL2
Cytokines, extracellular soluble mediators
CRIM1 (TGFβ interaction), CTGF, CYR61/CCN1, DKK3
(extracellular Wnt inhibitor), IGFBP4 (IGF binding), PLTP (lipid
metabolism),
Cytokine receptors and signaling ECM1, GAS6, GREM1, NBL1, NRP2, SDC1, SSC5D, VASN (TGFsignaling)
Cell surface molecules
Ig superfamily: CD248, THY1
Adhesion: CDH2, CDH11, CDH13, DAG1, ITGBL1
Others: OLFML2B, PROCR, PTPRK, VASN (TGF signaling)
Enzymes
Proteases: C1R, CFH, CTSK, ECM1, MMP13, MMP14, PAPPA,
PRSS23
Other enzymes: B4GALT1, ENPP1, ENPP2, LOX, LOXL1,
LOXL2
Golgi/endoplasmatic reticulum B4GALT1, FKBP10 (chaperon), GOLM1
Cytoskeleton DAG1, TAGLN
Intracellular signaling CTHRC1, PTPRK
Previous studies have identified several stroma-derived molecules that are important
for the maintenance and function of normal hematopoietic stem cells in the bone marrow
stem cell niches [28–32]. It can be seen from Table 4 that several of these stem cell regu-
lating proteins (e.g., several extracellular matrix and adhesion molecules) were included
among the 60 proteins showing undetectable levels for most patients when AML cells
were cultured alone but detectable levels for most MSC cultures supplemented with the
corresponding AML-CM (marked in Table 4; five extracellular matrix molecules, three
enzymes important for post-transcriptional modulation of matrix molecules, three soluble
cadherins). A total of 795 proteins showed detectable levels for 10 or fewer of the 40
patients when the AML cells were cultured alone; these 795 proteins reflect a heterogeneity
between patients with regard to their constitutive protein release and this heterogeneity
is reduced/eliminated only for 60 of these proteins when MSCs are present. Thus, the
presence of MSCs has a limited effect on this heterogeneity of the overall extracellular
protein release by primary human AML cells.
We performed an additional GO term analysis (using a GO tool) of these 60 proteins
found in 10 or fewer AML-CM samples but in at least 30 MSC/AML-CM samples. The
results of the analyses of cellular compartment and molecular functions are presented
in Table 5. Several highly significant GO terms were identified in all analyses. These
terms mainly reflect that the 60 proteins have important extracellular function and being
either extracellular matrix molecules or modulators of the extracellular matrix. Several
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proteins are also important for cell–cell or cell–matrix adhesion, are localized to the cell
surface membrane or are important for the binding of soluble mediators. Finally, the same
biological functions as in the analysis of cellular compartments/molecular functions were
also reflected identified in GO term analyses of biological processes and additional analyses
based on the KEGG and Uniprot databases. Taken together, this dominance of certain
protein subsets among the 60 proteins clearly illustrates that they are not identified by
coincidence, and the increased levels of these proteins are not caused by a random process.
Taken together, these analyses support the conclusion from Section 3.4. and suggest
that the presence of MSCs has a limited effect on the AML-associated heterogeneity of the
extracellular protein profile of the common MSC/AML cell microenvironment, i.e., only 60
of 795 proteins released for 10 or fewer patients are detected in the supernatant samples for
most patients in the presence of MSCs (see Table S4).
3.6. The Effect of MSCs on the AML-Associated Heterogeneity of of Their Common Extracellular
Protein Profile; Relatively Few of the Quantified Proteins Are Significantly Altered by the Presence
of MSCs
To further investigate the additional contribution of MSCs to the in vitro protein
release profile when these cells were influenced by the heterogeneous AML cells (i.e.,
incubated with AML-CM), we compared the levels of individual proteins in supernatants
from MSC/AML-CM cultures with the corresponding AML-CM. Only the 2304 proteins
with quantitative levels for at least four pairs of AML-CM and MSC/AML-CM were
included in this analysis. As the AML-CM was added to the MSCs at a 1:1 ratio, we
assumed a lower abundance of the AML-CM-derived proteins in the MSC/AML-CM
samples compared to AML-CM alone. For this reason we defined a significant effect
by a fold change criterion (i.e., of two-fold increase or four-fold decrease in MSC/AML-
CM relative to AML-CM) together with a statistical criterion (i.e., p-value < 0.05, paired
t-test). When analyzing the overall results, we observed significantly increased abundance
corresponding to more than a two-fold increase for 146 proteins in the MSC/AML-CM
cultures whereas only 26 proteins showed decreased abundance corresponding to at least a
four-fold decrease (Table S5). Thus, the presence of MSCs causes a significant quantitative
alteration in the extracellular levels only for a minority of the quantified proteins. Protein
interaction network analysis of these differently released proteins showed that the proteins
with increased levels in MSC/AML-CM cultures relative to the corresponding AML-CM
samples were involved especially in extracellular matrix (ECM) organization but also
related processes including glycosamin biosynthesis, extracellular protein release (i.e.,
platelet degranulation) and regulation of metabolism (Figure 7).
MSCs cultured in medium without AML-CM showed detectable release for 140 of
the 146 proteins that had significantly increased abundance in MSC/AML-CM culture
supernatants; thus, only a small minority of these proteins (CD82, ADAM17, SCP2, S100B,
CPNE3 and LRMP) was not detected in the MSC supernatants.
To conclude, these analyses described in this section further support the main con-
clusions from Sections 3.4 and 3.5; i.e., the presence of MSCs has a limited effect of the
AML-associated heterogeneity of the extracellular protein profile in the common microen-
vironment. In Sections 3.4 and 3.5, we described qualitative differences caused by MSCs,
whereas we analyzed MSC-induced differences for quantifiable proteins in the present
section. Additionally, for these proteins, we observed MSC effects, especially on extracel-
lular levels of matrix protein, but in addition the levels of mitochondrial matrix proteins
involved in the tricarboxylic acid cycle were altered (Figure 7 and Table S5).
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Table 5. GO term analyses of the 60 proteins released by a minority of patient samples (≤10) when AML cells were cultured alone but detected for most patient samples (≥30) when MSCs



















GO:0005615 58.3 13.4 4.4 35 60 402 2998 1.29 × 10−15 2.67 × 10−13 extracellular space
GO:0031012 45.0 8.0 5.6 27 60 240 2998 4.68 × 10−14 4.82 × 10−12 extracellular matrix
GO:0005576 53.3 17.5 3.0 32 60 525 2998 6.05 × 10−10 2.49 × 10−8 extracellular region
GO:0044420 20.0 1.8 10.9 12 60 55 2998 2.73 × 10−9 9.38 × 10−8 extracellular matrix component
GO:0005788 26.6 4.5 5.9 16 60 136 2998 1.43 × 10−8 4.21 × 10−7 endoplasmic reticulum lumen
GO:0005581 11.6 1.1 10.6 7 60 33 2998 8.81 × 10−6 0.000202 collagen trimer
GO:0009986 18.3 4.9 3.8 11 60 146 2998 0.000177 0.00331 cell surface
GO:0005796 8.3 0.9 9.6 5 60 26 2998 0.000282 0.00484 Golgi lumen
GO:0031224 30.0 13.0 2.3 18 60 391 2998 0.000543 0.0086 intrinsic component of membrane
GO:0016323 6.7 0.9 7.4 4 60 27 2998 0.00284 0.0325 basolateral plasma membrane
MOLECULAR FUNCTION
GO:0005509 25.5 5.1 5.0 14 55 152 2968 7.97 × 10−7 0.000223 calcium ion binding
GO:0050840 12.7 0.9 14.0 7 55 27 2968 1.64 × 10−6 0.00023 extracellular matrix binding
GO:0019838 14.5 1.4 10.0 8 55 43 2968 2.48 × 10−6 0.000231 growth factor binding
GO:0005044 7.3 0.4 18.0 4 55 12 2968 0.000152 0.00777 scavenger receptor activity
GO:0005178 10.9 1.7 6.5 6 55 50 2968 0.000443 0.0138 integrin binding
GO:0001968 7.3 0.6 11.4 4 55 19 2968 0.000672 0.0188 fibronectin binding
GO:0016641 5.5 0.2 20.2 3 55 8 2968 0.000848 0.0198
oxidoreductase activity, acting on the
CH-NH2 group of donors, oxygen
as acceptor
GO:0016015 3.6 0.1 54.0 2 55 2 2968 0.00191 0.0333 morphogen activity
GO:0019955 7.3 0.9 7.7 4 55 28 2968 0.00242 0.0398 cytokine binding
GO:0005201 7.3 1.0 7.4 4 55 29 2968 0.00271 0.042 extracellular matrix structuralconstituent
GO:0005539 10.9 2.5 4.4 6 55 74 2968 0.00293 0.042 glycosaminoglycan binding
GO:0004528 3.6 0.1 36.0 2 55 3 2968 0.00314 0.042 phosphodiesterase I activity
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3.7. Identification of AML Patient Subsets by a Clustering Analysis Based on the Protein Profile of
Supern tants Derived from MSC Cultures Supplemented with AML-Conditioned Media
We performed a hierarchical quantitative protein clustering analysis based on the
40 supernatants derived from cultures of MSCs in the presence of AML-CM. The clustering
analysis is presented in Figure S4 and a summary of these results is included in Figure 6.
Based on this analysis three patient clusters/subsets were identified (Figure S4), and these
clusters/subsets differed from the clusters identified in the analysis based on the AML-
CM alone (Figure 4). However, the dark brown/lower patient subcluster from the AML
constitutive release analysis (see Figure 4) included only patients from the left and middle
patient subclusters but no patients from the right of the MSC/AML-CM analysis (Figure
S4). This association between patients included in the lower dark brown (Figure 4) and
right cluster (Figure S4) reached statistical significance (Fisher exact test, p = 0.0038), an
observation further illustrating that patient heterogeneity detected in the proteomic analysis
of the constitutive extracellular AML cell release (Figure 4) is at least partly maintained
and thereby influences the extracell lar proteomic profiles when MSCs are cultured in the
presence of AML-CM. Our previous conclusion (Sections 3.4–3.6) is therefore s pported
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by this new clustering analysis; i.e., the presence of MSCs does not cancel out the AML-
associated heterogeneity with regard to the extracellular protein profile of their common
microenvironment (Figure 4). Finally, the patient clusters/subsets identified in this new
clustering analysis (Figure S4) did not differ significantly with regard to age, gender,
differentiation (FAB classification/CD34 expression), karyotype, Flt3/NPM1 abnormalities
or etiology (secondar versus de novo) (data not shown).
3.8. Both MSCs and AML Cells Show Extracellular Release of a Wide Range of Exosomal Proteins
We compared the proteins in our entire dataset to proteins annotated to the GO
term Exosome, and found 1043 overlapping proteins (Supplementary File 2); 340 of these
proteins were not expressed by the MSCs, whereas constitutive release of 729 of these
proteins were detected in at least 20 supernatants from AML cells cultured alone (i.e.,
AML-CM) and 127 proteins showed detectable levels in all 40 patient samples. Table S6
shows all exosomal proteins detected in AML-CM, and we have marked with yellow all
proteins that are included in the top 100 ranked exosomal proteins (http://exocarta.org/
exosome_markers_new, accessed on 15 November 2020). All AML cells expressed 41 of
these top-ranked proteins, an observation suggesting that exosomal release is an important
mechanism for extracellular protein release by primary human AML cells.
When comparing the overall results for these 1043 exosomal proteins, significantly
increased levels were detected only for 75 of them when MSC/AML-CM were compared
with the corresponding AML-CM. However, the levels in the MSC/AML-CM cultures
were significantly 2-fold increased for 187 proteins when compared with MSCs cultured
alone, whereas 2-fold decreased levels were detected only for 101 proteins (only 14 pro-
teins showing four-fold reduction). Thus, exosomal release seem to be maintained as an
important mechanism of extracellular protein release also in MSC/AML-CM cultures.
3.9. Culture of MSCs in the Presence of AML-CM; the Supernatant Levels of MSC-Specific
Proteins Are Decreased in the Presence of AML-CM
The protein release profiles of the MSCs were highly reproducible in repeated inde-
pendent experiments (Figure S5), and we identified 61 MSC-specific proteins (i.e., proteins
detected in AML-CM for ≤2 patients and in MSC cultured alone for ≥4 samples, Table S2).
However, when we investigated supernatants from MSC cultures supplemented with AML-
CM (i.e., MSC/AML-CM) from all 40 patients only 9 of these 61 proteins were detected
for ≥30 patients, 28 proteins for 20–29 patients, 10 proteins for 10–19 patients, 8 proteins
for 5–9 patients and 5 proteins for fewer than five (7 proteins) or none (1 proteins) of
the patients. Thus, even though all these proteins were released at detectable levels only
or mainly by MSCs, for several of them the detectable levels could only be quantified
for a minority of the patients when AML-CM was present during culture. Thus, AML
patients are heterogeneous also with regard to their effects on the constitutive release of
MSC-specific proteins.
We also performed statistical comparisons of the abundance of MSC-specific proteins
for MSC/AML-CM versus MSC cultures prepared in medium alone. None of these proteins
were significantly increased when AML-CM was present, whereas 45 proteins (including 3
isoforms of POSTN) were significantly decreased compared with MSC medium controls
(Table S7). Thus, the AML effect on MSC-associated protein release differs between patients
(see above), but the effect of this intercellular crosstalk also differs between proteins with
decreased release for a subset of proteins including several extracellular matrix molecules.
Previous studies of ECM expression at the mRNA level have described a 15-ECM
gene expression signature that is associated with survival for patients receiving intensive
antileukemic treatment [33–35]. Ten of the proteins encoded by these 15 genes could be
detected in our present proteomic studies (Table S8), and five of them were not released at
detectable levels by MSCs. The release of these ten detectable proteins varied between AML
cells/patients; Col18A1 was only released at detectable levels for five patients whereas
myeloblastin was detected for 31 patients. Furthermore, we investigated CD44 release
in addition to the ECM signature proteins because it can bind to a wide range of extra-
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cellular matrix molecules [36–43], it seems to be an important normal stem cell regulator
in the endothelial niche [43] and it is involved in interactions between AML cells and
AML-supporting endothelial cells [42]. It is also associated with a chemoresistant AML
cell phenotype [44,45] although it is not regarded as an established prognostic factor in
routine clinical practice [1]. The soluble form of CD44 was released both by MSCs and
by AML cells derived from 39 out of 40 patients. Only three of these 11 proteins showed
significantly altered levels in MSC/AML-CM cultures compared with AML-CM and only
one (ADAM17) when considering proteins with two-fold increase or four-fold decrease
(Table S8). Thus, MSCs seem to have only a limited effect on this AML-associated ECM
signature that possibly has a prognostic impact.
4. Discussion
Extracellular protein release is important for the formation of extracellular matrix and
for communication between neighboring cells both in normal and leukemic hematopoiesis.
In the present study, we used a proteomic strategy to characterize and compare the constitu-
tive protein release by AML cells derived from 40 consecutive patients, and we investigated
how this heterogeneity is modified by normal bone marrow MSCs. AML cells generally
released a higher number of quantifiable proteins than MSC, but this release varied consid-
erably between patients both regarding the number and nature of the quantified proteins.
In this study we used highly enriched cell populations of MSCs derived from a healthy
individual. Furthermore, the enriched AML cells were derived from a consecutive group
of patients with a high percentage and/or absolute number of leukemic cells among
circulating leukocytes; highly enriched AML cell populations could therefore be prepared
by density gradient separation alone [9,46,47]. Flow cytometric analyses confirmed that
at least 90% of these gradient-separated cells were AML cells. Therefore, our results may
only be representative for the subset of AML patients with circulating leukemic cells but
not for patients without circulating blast cells. However, since the level of circulating AML
cells has a relatively weak prognostic impact in patients receiving intensive and potentially
curative treatment [48–52], our present results may be representative with regard to clinical
chemosensitivity also for other patients. Finally, due to this consecutive selection, a large
subset of our patients were elderly and/or unfit, and therefore only 19 patients received
intensive and potentially curative therapy [1]. Four of these 19 patients died from toxicity,
i.e., before the planned intensive treatment was completed. Due to the relatively low
number of patients that completed the intensive therapy, survival analyses could not be
included in this study.
Many studies suggest that AML relapse is derived from residual leukemic stem cells
(for a detailed discussion and additional references see [5,53]), and the risk of relapse will
therefore depend on the chemosensitivity of the minority of AML stem cells. However, the
genetic abnormalities and the biological characteristics associated with these abnormalities
(including chemosensitivity [1]) also seem to be reflected not only in the leukemic stem
cells but also in the majority of more mature cells in the hierarchically organized AML
cell population. Several studies have therefore demonstrated that the biological charac-
teristics of the total AML cell population are associated with relapse risk and survival,
including both mRNA gene expression profiles, noncoding RNA profiles, proteomic and
phosphoproteomic profile as well as epigenetic and metabolic regulation [54–61]. For these
reasons we regard investigation of the overall AML cell populations in our present study
to be relevant.
The proteins in the AML culture supernatants (i.e., the AML-conditioned media)
are released through various mechanisms. First, proteins can be released by exocytosis
or the release of exosomes and this is probably the case both for AML cells and MSCs
because several exosomal proteins were detected in the conditioned media. Some of the
extracellular matrix proteins are very large (e.g., collagens) and recruitment of special-
ized proteins for packing of these molecules may be required for vesicle formation and
subsequent extracellular release [62]. Second, release caused by proteolytic cleavage of
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cell surface molecules is also possible. Finally, we did not see increased levels of necrotic
cells in the MSC cultures, but the primary AML cells showed expected spontaneous or
stress-induced in vitro apoptosis during culture [23]. However, even though we cannot
exclude that protein release from apoptotic/necrotic cells contributes to the protein release
profiles, in our opinion, this mechanism is probably less important because the clustering
or subclassification of patients (Figure 4) did not show any significant association with the
cell viability at the end of the culture period.
We performed an unsupervised hierarchical clustering analysis based on the consti-
tutive protein release of the primary AML cells (Figure 4). This analysis was based on
those proteins that could be detected for at least 50% of the patients. We identified two
main clusters, and each of them could be further divided into two subclusters. Our patient
group is relatively small and we could only detect an association between this patient
subclassification and secondary AML, whereas no significant associations with genetic
abnormalities could be detected. However, the associations between protein release patient
clusters and secondary leukemia [63,64] as well as constitutive cytokine release [8] suggest
that the overall protein release profile has a prognostic impact.
In a previous study, we observed that the constitutive AML cell release of cytokines
and proteases/protease regulators varied considerably between patients, and we could
identify three patient subsets characterized by generally high, intermediate and low consti-
tutive release, respectively [8]. Generally high constitutive release was then associated with
a favorable prognosis and increased overall survival. We could investigate the constitutive
cytokine release in this experimental model for a subset of 33 consecutive patients, and
a cluster analysis of these data confirmed that the patients formed three main clusters
(Figure S3), as described previously [8]. Furthermore, the subclassification of patients
based on the more limited constitutive cytokine/protease/protease regulators release was
significantly associated with the subclassification based on the general protein release
profile (Figure 4 and Figure S3). Taken together, these results suggest that generally high
extracellular protein release (including high constitutive cytokine release) is a part of a
functional AML cell phenotype that shows high clinical chemosensitivity and thereby a fa-
vorable prognosis. A possible hypothesis for the mechanisms behind this observation could
be that these patients/AML cells are more dependent on communication with and thereby
external support from extracellular matrix and/or neighboring cells for proliferation and
survival, thus a dependency making them more chemosensitive.
Both MSCs and primary AML cells released a wide range of proteases or regulators
of proteases. Protease activity can be important for the communication between cells
through several mechanisms; the contribution of the various mechanisms has been investi-
gated more in detail for certain proteases (e.g., the ADAM family) [25,65], whereas less is
known for many others with regard to their possible roles in cellular communication. First,
proteases are important for the regulation of cytokine activity; cytokines can be activated
through proteolytic processing, as described for several chemokines and members of the IL1
family [65,66]. Both the present and previous studies show that chemokines as well as IL1
family members can be constitutively released by primary AML cells [8,26,67]. The effects
of various proteases on IL1 family cytokines with the possibility of cleavage at many differ-
ent sites clearly illustrate the complexity of protease effects on cellular communication [66].
Proteases are also involved in the activation of hepatocyte growth factor [68]. Second,
certain serine proteases can trigger both cytokine expression/release and cleavage; this
has been described both for IL6, TNFα and IL8/CXCL8 (all three can be secreted by AML
cells), and such protease effects can be mediated by Toll-like receptors (TLRs) that also are
expressed by primary AML cells [69,70]. Proteases and cytokines can also be colocalized
in the same secretory vesicles [71]. Third, certain proteases or protease inhibitors can
function as signaling molecules and/or activate receptor signaling [72]. Finally, several
ADAM proteases can cleave a wide range of membrane molecules, e.g., cytokine receptors
and adhesion molecules with biological activity, and processing of extracellular or trans-
membrane protein domains can lead to release of intracellular domains with subsequent
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signal transduction [73,74]. Thus, proteases can be important for cellular communication
through several mechanisms, including the communication between leukemic cells and
their stromal cells/molecules. Further studies are therefore needed to clarify which role
the various proteases play in leukemogenesis.
In our present study, we compared the constitutive protein release by primary AML
cells (i.e., protein abundance in AML-CM) with the protein abundance when MSCs were
cultured in the presence of these conditioned media from all 40 patients. A small subset
of proteins showed detectable release by the leukemic cells only for a small minority of
patients, whereas detectable release was observed for most patients when investigating
the MSC/AML-CM culture supernatants. Even though our analysis of the overall protein
release profiles suggests that patient heterogeneity is mainly maintained in the presence
of MSCs, the heterogeneity of the overall extracellular protein release is reduced by the
crosstalk between MSCs and primary AML cells mediated through the extracellular release
of protein mediators; the MSC release decreases the heterogeneity especially for extracel-
lular matrix molecules but also for several proteases (i.e., protein modifiers) and soluble
adhesion molecules (Table 4). Many of these extracellular proteins are important for the
function of bone marrow stem cell niches (Table 4) and may also be important for the
function of these niches in leukemogenesis and/or cancer metastasizing [28–32].
As discussed above, cells can release proteins to the extracellular space through var-
ious mechanisms, e.g., proteolysis of surface proteins and through exosomes [75,76]. In
the present study, we did not analyze exosomes separately and for this reason we cannot
evaluate the relative contribution of each of these two mechanisms, but the high extra-
cellular levels of several proteases suggest that proteolytic cleavage of surface molecules
contributes [65–74]. However, many of our detected proteins belong to the GO term Exo-
somes, an observation suggesting that exosomal release is also involved. This is further
supported by the high number of top-100 listed exosomal proteins detected in our su-
pernatants. Even though the overall exosomal protein profile varied between patients,
many of these proteins were detected for all or almost all patients. Exosomes influence
their target cells through binding to surface receptors, fusion with the cell membrane
and subsequent intracellular delivery of molecules, or internalization and subsequent
fusion with endosomes followed by transcytosis or lysosomal maturation [75,76]. Exo-
somes can then influence intracellular processes through delivery of proteins, µRNA and
metabolites [77–82].
Previous studies of ECM expression at the mRNA level have described a 15-ECM
gene expression signature that is associated with survival for patients receiving intensive
antileukemic treatment [33–36]. Ten of the proteins encoded by these 15 genes could also
be detected in our present protein studies (Table S8). Our present results at the protein
level suggest that the presence of MSCs does not cause any major modulation of this
AML-associated prognostic matrix profile.
We investigated 40 consecutive newly diagnosed patient; these patients should there-
fore be regarded as representative with regard to AML heterogeneity but at the same time
they will also be heterogeneous with regard to received antileukemic treatment because
approximately half of them will thereby be elderly and/or unfit patients that cannot receive
the most intensive treatment (e.g., intensive induction/consolidation, high-dose cytarabine,
allogeneic or autologous stem cell transplantation). Due to these differences in intensity
and intent (cure versus stabilization) of the antileukemic therapy the patient numbers
are too small to allow analysis of differences in survival between various patient subsets.
However, due to the higher frequency of elderly patients with secondary AML in the dark
yellow cluster in Figure 4, this patient subset will also include a larger fraction of patients
not receiving intensive therapy.
Even though AML patients are heterogeneous with regard to extracellular protein
release, our study also described several proteins that reach high extracellular levels for all
or almost all patients when AML cells were cultured alone (see the Supplementary File 2).
Several additional proteins also reached high levels when MSCs were cultured with AML-
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conditioned medium (Table 4, Table S4). These proteins can be considered as possible ther-
apeutic targets for AML in general, whereas the proteins detected only for (minor) patient
subsets should probably be regarded as therapeutic targets in individualized treatment.
Our previous studies have described differences in proteomic profiles between pre-
treatment AML cells derived from patients that become long-term survivors and patients
who later die from chemoresistant relapse despite intensive therapy [46], and between cells
isolated at the time of first diagnosis and at the time of chemoresistant relapse for the same
patients [55]. We have also described AML cell characteristics that seem to be associated
with aging [56]. Our present study, together with a previous [12] study, also suggests that
both leukemic and non-leukemic supportive cells contribute to the proteomic profile of
the common bone marrow microenvironment. In our opinion, the next step should be to
include proteomic analyses as parts of clinical studies to investigate whether these profiles
have independent prognostic impact and to possibly allow identification of new single
protein biomarkers or therapeutic targets. Such a strategy would require standardized
procedures for AML cell sampling and separation/enrichment. One should also try to
investigate the possible importance of the extracellular bone marrow microenvironment in
these studies. In our opinion, it will be difficult to use in vitro cell culture in routine clinical
practice, but proteomic analysis of bone marrow plasma should be an alternative. This
would require careful standardization of sampling and preparation of the bone marrow
plasma samples, but the advantage with bone marrow plasma would probably be that it
reflects the overall contribution of both leukemic and various non-leukemic bone marrow
stromal cells to the common extracellular microenvironment. Such approaches used during
and following antileukemic therapy have potential to elucidate molecular mechanisms
involved in leukemogenesis, chemoresistance and development of relapse from residual
leukemic stem cells.
Both conventional intensive chemotherapy and new AML-targeting therapy will prob-
ably alter the protein release by the leukemic cells. Previous studies have shown that
conventional cytotoxic drugs will also influence various stromal cells (osteoblasts, endothe-
lial cells, immunocompetent cells), including their release of soluble mediators [83,84].
Future studies should therefore try to characterize the effects of various therapeutic strate-
gies on the constitutive protein release by non-leukemic stromal cells.
Targeting of the molecular interactions between malignant cells and their neighboring
bone marrow stromal cells is a possible therapeutic strategy in the treatment of cancer [85].
Our present results show that AML patients are very heterogeneous with regard to the
leukemic cell contribution to the extracellular matrix. Although the presence of MSCs
has only a minor effect on the overall protein release profile by primary AML cells, they
reduce patient heterogeneity with regard to extracellular matrix molecules including
matrix molecules that are important for the function of the bone marrow stem cell niches.
Targeting of the cancer cell/matrix interactions may therefore become possible not only
as an individualized therapeutic strategy (i.e., be dependent on patient heterogeneity)
but possibly also as a common strategy targeting interactions with bone marrow matrix
molecules that are detected for most/all AML patients.
5. Conclusions
Primary human AML cells show a wide variation in their constitutive extracellular
protein release during in vitro culture both regarding the number of proteins and the
function of the released proteins. Bone marrow MSCs also show constitutive protein
release especially of extracellular matrix proteins and thereby reduce patient heterogeneity
with regard to a minor subset of extracellularly released protein. A large number of
exosomal proteins are released both by the AML cells and MSC, suggesting that exosomal
release is an important mechanism for extracellular protein release and communication
with neighboring cells in the bone marrow microenvironment both for AML cells and MSCs.
Therapeutic targeting of exosomal release or molecular interactions between AML cells
and the extracellular matrix may represent possible therapeutic strategies in human AML.
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